Company Algernon Pharmaceuticals Inc.

Equities

AGN

CA01559R4008

Biotechnology & Medical Research

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Quarterly revenue - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Canadian Securities Exchange Other stock markets 19:50:41 10/05/2024 BST			5-day change	1st Jan Change
0.125 ^CAD	+13.64%		+13.64%	+92.31%

04-30	Algernon Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024	CI
04-10	Algernon Pharmaceuticals Inc. announced that it has received CAD 0.017 million in funding	CI

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Companyâs lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

Managers	Title	Age	Since
Chris Moreau CEO	Chief Executive Officer	59	28/02/18
James Kinley DFI	Director of Finance/CFO	45	30/11/21
Christopher Bryan COO	Chief Operating Officer	41	28/02/21
Ahmad Khalil CTO	Chief Tech/Sci/R&D Officer	-	28/02/21

Members of the board	Title	Age	Since
Harry Bloomfield CHM	Chairman	79	07/09/21
Chris Moreau CEO	Chief Executive Officer	59	28/02/18
Mark Williams BRD	Director/Board Member	52	21/09/21
James Kinley DFI	Director of Finance/CFO	45	30/11/21
Raj Attariwala BRD	Director/Board Member	55	25/10/15
Howard Gutman BRD	Director/Board Member	-	27/02/22

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	21,840,722	21,665,319 ( 99.20 %)	0	99.20 %

Name	Equities	%	Valuation
AlphaNorth Asset Management 15.00 %	3,002,880	15.00 %	246 236 $
Chris Moreau 5.193 %	1,039,502	5.193 %	85 239 $
James Kinley 4.052 %	810,992	4.052 %	66 501 $
Harry Bloomfield 2.155 %	431,332	2.155 %	35 369 $
Howard Gutman 0.8652 %	173,180	0.8652 %	14 201 $
Raj Attariwala 0.5733 %	114,760	0.5733 %	9 410 $
Mark Williams 0.2238 %	44,800	0.2238 %	3 674 $
Christopher Bryan 0.000000 %	0	0.000000 %	- $

Algernon Pharmaceuticals, Inc.

601 West Broadway Street Suite 400

V5Z 4C2, Vancouver

+604-398-4175

http://www.algernonpharmaceuticals.com

address Algernon Pharmaceuticals Inc.(AGN)

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
ALGERNON PHARMACEUTICALS INC.	+92.31%	1.98M
VERTEX PHARMACEUTICALS INCORPORATED	+3.91%	109B
REGENERON PHARMACEUTICALS, INC.	+10.87%	105B
ARGENX SE	+1.28%	22.25B
BIONTECH SE	-13.14%	22.09B
GENMAB A/S	-7.05%	18.68B
WUXI APPTEC CO., LTD.	-38.36%	17.58B
BEIGENE, LTD.	-10.66%	16.85B
NEUROCRINE BIOSCIENCES, INC.	+3.75%	13.76B
SAREPTA THERAPEUTICS, INC.	+36.70%	12.46B

Bio Therapeutic Drugs